Array BioPharma Company Profile (NASDAQ:ARRY)

About Array BioPharma (NASDAQ:ARRY)

Array BioPharma logoArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ARRY
  • CUSIP: 04269X10
  • Web: www.arraybiopharma.com
Capitalization:
  • Market Cap: $1.5 billion
  • Outstanding Shares: 170,800,000
Average Prices:
  • 50 Day Moving Avg: $8.26
  • 200 Day Moving Avg: $9.01
  • 52 Week Range: $3.10 - $13.40
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -24.36
  • P/E Growth: -0.91
Sales & Book Value:
  • Annual Revenue: $43.66 million
  • Price / Sales: 34.31
  • Book Value: $0.07 per share
  • Price / Book: 125.29
Profitability:
  • EBIDTA: ($100,010,000.00)
  • Net Margins: -77.44%
  • Return on Equity: -1,187.18%
  • Return on Assets: -47.96%
Debt:
  • Debt-to-Equity Ratio: 11.42%
  • Current Ratio: 3.88%
  • Quick Ratio: 3.47%
Misc:
  • Average Volume: 2.79 million shs.
  • Beta: 2.18
  • Short Ratio: 6.43
 

Frequently Asked Questions for Array BioPharma (NASDAQ:ARRY)

What is Array BioPharma's stock symbol?

Array BioPharma trades on the NASDAQ under the ticker symbol "ARRY."

How were Array BioPharma's earnings last quarter?

Array BioPharma Inc. (NASDAQ:ARRY) issued its earnings results on Wednesday, August, 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.21) by $0.04. The company earned $33.80 million during the quarter, compared to analysts' expectations of $28.64 million. Array BioPharma had a negative net margin of 77.44% and a negative return on equity of 1,187.18%. The firm's quarterly revenue was down 21.8% compared to the same quarter last year. During the same period last year, the company posted ($0.17) earnings per share. View Array BioPharma's Earnings History.

When will Array BioPharma make its next earnings announcement?

Array BioPharma is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Array BioPharma.

Where is Array BioPharma's stock going? Where will Array BioPharma's stock price be in 2017?

7 analysts have issued 12-month target prices for Array BioPharma's shares. Their predictions range from $8.00 to $14.00. On average, they expect Array BioPharma's stock price to reach $11.86 in the next year. View Analyst Ratings for Array BioPharma.

What are analysts saying about Array BioPharma stock?

Here are some recent quotes from research analysts about Array BioPharma stock:

  • 1. According to Zacks Investment Research, "Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. " (8/11/2017)
  • 2. Cowen and Company analysts commented, "We see ARRY's decision to withdraw the NRAS NDA as prudent given the known modest efficacy benefit. The NRAS-mutant melanoma opportunity represented a modest 6% of our base model DCF, thus we lower our PT modestly from $15 to $14. We view recent share weakness and the passing of this 'risk' event as an especially attractive opportunity to firmly reiterate our Outperform rating on ARRY shares." (3/20/2017)

Who are some of Array BioPharma's key competitors?

Who are Array BioPharma's key executives?

Array BioPharma's management team includes the folowing people:

  • Kyle A. Lefkoff, Independent Chairman of the Board
  • Ron R. Squarer, Chief Executive Officer, Director
  • Jason Haddock, Chief Financial Officer
  • Andrew R. Robbins, Chief Operating Officer
  • Nicholas A. Saccomano Ph.D., Chief Scientific Officer
  • John R. Moore, Vice President, General Counsel, Secretary
  • Victor Sandor, Chief Medical Officer
  • Shalini Sharp, Director
  • Charles M. Baum M.D., Ph.D., Independent Director
  • Gwendolyn A. Fyfe M.D., Independent Director

Who owns Array BioPharma stock?

Array BioPharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.49%), FMR LLC (10.85%), BlackRock Inc. (7.61%), State Street Corp (5.59%), Franklin Resources Inc. (5.24%) and Pinnacle Associates Ltd. (1.79%). Company insiders that own Array BioPharma stock include Charles M Baum and Redmile Group, Llc. View Institutional Ownership Trends for Array BioPharma.

Who sold Array BioPharma stock? Who is selling Array BioPharma stock?

Array BioPharma's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Cambiar Investors LLC, Canada Pension Plan Investment Board, Bank of Nova Scotia, Columbus Circle Investors, Chicago Equity Partners LLC, Alliancebernstein L.P. and TD Asset Management Inc.. Company insiders that have sold Array BioPharma stock in the last year include Charles M Baum and Redmile Group, Llc. View Insider Buying and Selling for Array BioPharma.

Who bought Array BioPharma stock? Who is buying Array BioPharma stock?

Array BioPharma's stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Vanguard Group Inc., State Street Corp, Quantitative Investment Management LLC, Teachers Advisors LLC, Goldman Sachs Group Inc., Handelsbanken Fonder AB and First Trust Advisors LP. View Insider Buying and Selling for Array BioPharma.

How do I buy Array BioPharma stock?

Shares of Array BioPharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Array BioPharma's stock price today?

One share of Array BioPharma stock can currently be purchased for approximately $8.77.


MarketBeat Community Rating for Array BioPharma (NASDAQ ARRY)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  237 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  324
MarketBeat's community ratings are surveys of what our community members think about Array BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Array BioPharma (NASDAQ:ARRY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $11.86 (35.20% upside)

Analysts' Ratings History for Array BioPharma (NASDAQ:ARRY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017Piper Jaffray CompaniesReiterated RatingBuy$14.00HighView Rating Details
8/9/2017Cantor FitzgeraldSet Price TargetBuy$13.00HighView Rating Details
8/10/2017Stifel NicolausReiterated RatingBuy$13.00HighView Rating Details
5/6/2017Jefferies Group LLCSet Price TargetBuy$8.00HighView Rating Details
5/3/2017J P Morgan Chase & CoUpgradeNeutral -> Overweight$9.00 -> $10.00LowView Rating Details
3/20/2017Cowen and CompanyLower Price TargetOutperform$14.00HighView Rating Details
1/30/2017Leerink SwannDowngradeOutperform -> Market Perform$11.00N/AView Rating Details
6/2/2016SunTrust Banks, Inc.Initiated CoverageBuy$7.00N/AView Rating Details
(Data available from 8/18/2015 forward)

Earnings

Earnings History for Array BioPharma (NASDAQ:ARRY)
Earnings by Quarter for Array BioPharma (NASDAQ:ARRY)
Earnings History by Quarter for Array BioPharma (NASDAQ ARRY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017        
8/9/2017Q4 2017($0.21)($0.17)$28.64 million$33.80 millionViewListenView Earnings Details
5/10/2017Q3 2017($0.16)($0.21)$38.28 million$33.28 millionViewN/AView Earnings Details
2/9/2017Q2 2017($0.18)($0.14)$31.90 million$44.50 millionViewListenView Earnings Details
11/1/2016Q117($0.16)($0.20)$32.47 million$39.30 millionViewListenView Earnings Details
8/4/2016Q416($0.14)($0.17)$41.51 million$43.20 millionViewListenView Earnings Details
5/3/2016Q316($0.12)($0.16)$30.35 million$43.00 millionViewListenView Earnings Details
2/2/2016Q216($0.06)($0.17)$32.70 million$35.40 millionViewListenView Earnings Details
11/4/2015Q116($0.18)($0.15)$14.02 million$16.20 millionViewListenView Earnings Details
8/3/2015Q415($0.16)($0.09)$10.29 million$12.30 millionViewListenView Earnings Details
5/4/2015Q315($0.01)$0.37$6.00 million$6.60 millionViewListenView Earnings Details
2/3/2015Q215($0.20)($0.06)$10.20 million$26.92 millionViewListenView Earnings Details
11/4/2014Q115($0.22)($0.21)$6.35 million$6.07 millionViewListenView Earnings Details
8/12/2014Q414($0.23)($0.22)$8.10 million$6.00 millionViewListenView Earnings Details
4/29/2014Q314($0.21)($0.20)$9.40 million$7.80 millionViewListenView Earnings Details
2/4/2014Q214($0.16)($0.13)$13.49 million$14.10 millionViewListenView Earnings Details
10/31/2013Q114($0.18)($0.13)$11.20 million$14.20 millionViewListenView Earnings Details
8/7/2013Q4 2013($0.13)($0.06)$16.13 million$25.40 millionViewListenView Earnings Details
5/6/2013Q3 2013($0.14)($0.19)$14.54 million$10.00 millionViewListenView Earnings Details
2/4/2013Q2 2013($0.14)($0.10)$16.52 million$18.40 millionViewListenView Earnings Details
10/29/2012Q113($0.15)($0.13)$16.70 million$15.80 millionViewN/AView Earnings Details
8/13/2012($0.11)($0.09)ViewN/AView Earnings Details
4/30/2012($0.16)($0.11)ViewN/AView Earnings Details
1/30/2012($0.12)($0.06)ViewN/AView Earnings Details
5/2/2011($0.25)($0.20)ViewN/AView Earnings Details
1/31/2011($0.28)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Array BioPharma (NASDAQ:ARRY)
2017 EPS Consensus Estimate: ($0.94)
2018 EPS Consensus Estimate: ($1.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.22)($0.21)($0.22)
Q2 20173($0.27)($0.20)($0.22)
Q3 20173($0.31)($0.22)($0.25)
Q4 20173($0.29)($0.21)($0.25)
Q1 20182($0.31)($0.19)($0.25)
Q2 20182($0.32)($0.18)($0.25)
Q3 20182($0.36)($0.18)($0.27)
Q4 20182($0.26)($0.21)($0.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Array BioPharma (NASDAQ:ARRY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Array BioPharma (NASDAQ:ARRY)
Insider Ownership Percentage: 2.60%
Institutional Ownership Percentage: 96.27%
Insider Trades by Quarter for Array BioPharma (NASDAQ:ARRY)
Institutional Ownership by Quarter for Array BioPharma (NASDAQ:ARRY)
Insider Trades by Quarter for Array BioPharma (NASDAQ:ARRY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/28/2017Charles M BaumDirectorSell25,000$9.27$231,750.00View SEC Filing  
9/28/2016Redmile Group, LlcMajor ShareholderSell2,492,578$6.36$15,852,796.08View SEC Filing  
9/15/2016Redmile Group, LlcMajor ShareholderBuy400,000$3.51$1,404,000.00View SEC Filing  
1/20/2016Redmile Group, LlcMajor ShareholderBuy300,000$3.19$957,000.00View SEC Filing  
1/12/2016Redmile Group, LlcMajor ShareholderBuy75,000$3.60$270,000.00View SEC Filing  
1/11/2016Redmile Group, LlcMajor ShareholderBuy925,000$3.67$3,394,750.00View SEC Filing  
10/1/2015Redmile Group, LlcMajor ShareholderBuy782,592$4.58$3,584,271.36View SEC Filing  
8/25/2015Redmile Group, LlcMajor ShareholderBuy790,000$5.38$4,250,200.00View SEC Filing  
8/10/2015Redmile Group, LlcMajor ShareholderBuy1,048,993$5.80$6,084,159.40View SEC Filing  
3/3/2015Kyle LefkoffDirectorSell70,000$8.00$560,000.00View SEC Filing  
3/2/2015Andrews R RobbinsSVPSell21,576$8.25$178,002.00View SEC Filing  
3/2/2015Ron SquarerCEOSell40,000$8.25$330,000.00View SEC Filing  
9/16/2013Liam RatcliffeDirectorSell1,673,172$6.08$10,172,885.76View SEC Filing  
9/6/2013Liam RatcliffeDirectorSell577,286$5.79$3,342,485.94View SEC Filing  
8/2/2013John R MooreVPSell75,384$7.02$529,195.68View SEC Filing  
7/23/2013John R MooreVPSell5,000$6.50$32,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Array BioPharma (NASDAQ:ARRY)
Latest Headlines for Array BioPharma (NASDAQ:ARRY)
Source:
DateHeadline
prnewswire.com logoArray BioPharma Appoints Curtis Oltmans As General Counsel - PR Newswire (press release)
www.prnewswire.com - August 15 at 10:03 PM
finance.yahoo.com logoArray BioPharma Appoints Curtis Oltmans As General Counsel
finance.yahoo.com - August 14 at 9:29 PM
finance.yahoo.com logoArray BioPharma, Inc. :ARRY-US: Earnings Analysis: 2017 By the Numbers : August 14, 2017
finance.yahoo.com - August 14 at 4:28 PM
americanbankingnews.com logoQ1 2018 Earnings Estimate for Array BioPharma Inc. (ARRY) Issued By Jefferies Group
www.americanbankingnews.com - August 14 at 7:38 AM
americanbankingnews.com logoZacks: Brokerages Expect Array BioPharma Inc. (NASDAQ:ARRY) Will Post Quarterly Sales of $29.49 Million
www.americanbankingnews.com - August 14 at 5:04 AM
nasdaq.com logoArray BioPharma Inc (ARRY) Files 10-K for the Fiscal Year Ended on June 30, 2017 - Nasdaq
www.nasdaq.com - August 12 at 3:49 PM
americanbankingnews.com logoArray BioPharma Inc. (ARRY) Upgraded at Zacks Investment Research
www.americanbankingnews.com - August 11 at 9:42 PM
americanbankingnews.com logoArray BioPharma Inc. to Post FY2021 Earnings of $0.73 Per Share, Jefferies Group Forecasts (NASDAQ:ARRY)
www.americanbankingnews.com - August 11 at 5:22 PM
americanbankingnews.com logoArray BioPharma Inc. (NASDAQ:ARRY) to Post FY2018 Earnings of ($1.25) Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - August 11 at 3:56 PM
finance.yahoo.com logoIHS Markit Score Update: Drop in demand for ETFs holding Array Biopharma Inc is a negative sign for its shares
finance.yahoo.com - August 11 at 3:34 AM
seekingalpha.com logoArray BioPharma's (ARRY) CEO Ron Squarer on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - August 10 at 10:34 PM
finance.yahoo.com logoArray BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2017
finance.yahoo.com - August 10 at 10:34 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Array Biopharma Inc.
finance.yahoo.com - August 10 at 10:34 PM
finance.yahoo.com logoArray BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : ARRY-US : August 10, 2017
finance.yahoo.com - August 10 at 5:29 PM
americanbankingnews.com logoQ1 2018 Earnings Estimate for Array BioPharma Inc. (NASDAQ:ARRY) Issued By SunTrust Banks
www.americanbankingnews.com - August 10 at 12:08 PM
finance.yahoo.com logoEdited Transcript of ARRY earnings conference call or presentation 9-Aug-17 1:00pm GMT
finance.yahoo.com - August 10 at 2:15 AM
prnewswire.com logoArray BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2017 - PR Newswire (press release)
www.prnewswire.com - August 9 at 4:12 PM
seekingalpha.com logoArray BioPharma's (ARRY) CEO Ron Squarer on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 9 at 4:12 PM
finance.yahoo.com logoArray BioPharma reports 4Q loss
finance.yahoo.com - August 9 at 4:11 PM
americanbankingnews.com logoArray BioPharma Inc. (ARRY) Releases Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - August 9 at 3:03 PM
fool.com logoHere's Why Array BioPharma Inc. Fell 13.7% in July - Motley Fool
www.fool.com - August 8 at 2:57 AM
americanbankingnews.com logoArray Biopharma Inc (ARRY) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 5 at 8:44 AM
finance.yahoo.com logoArray BioPharma, Inc. – Value Analysis (NASDAQ:ARRY) : August 5, 2017
finance.yahoo.com - August 4 at 9:23 PM
finance.yahoo.com logoArray BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2017 On August 9, 2017
finance.yahoo.com - August 3 at 5:30 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Array BioPharma Inc. (NASDAQ:ARRY) Will Announce Quarterly Sales of $30.60 Million
www.americanbankingnews.com - July 27 at 12:50 PM
americanbankingnews.com logoArray BioPharma Inc. (NASDAQ:ARRY) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:22 AM
finance.yahoo.com logoArray BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : ARRY-US : July 24, 2017
finance.yahoo.com - July 24 at 1:01 PM
nasdaq.com logoNew Strong Sell Stocks for July 20th - Nasdaq
www.nasdaq.com - July 20 at 5:31 PM
bizjournals.com logoColorado biotech makes deal with industry giant - Denver Business Journal
www.bizjournals.com - July 18 at 5:33 PM
americanbankingnews.com logoArray BioPharma Inc. (NASDAQ:ARRY) Given a $14.00 Price Target by Piper Jaffray Companies Analysts
www.americanbankingnews.com - July 18 at 5:31 PM
businesswire.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of ... - Business Wire (press release)
www.businesswire.com - July 14 at 10:55 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Array BioPharma Inc.
finance.yahoo.com - July 14 at 5:54 PM
finance.yahoo.com logoETFs with exposure to Array BioPharma, Inc. : July 12, 2017
finance.yahoo.com - July 12 at 4:31 PM
americanbankingnews.com logoArray BioPharma Inc. (NASDAQ:ARRY) Downgraded by Zacks Investment Research
www.americanbankingnews.com - July 11 at 11:26 PM
americanbankingnews.com logoArray BioPharma Inc. (NASDAQ:ARRY) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 11 at 8:26 AM
nasdaq.com logoImplied Volatility Surging for Array BioPharma Inc. (ARRY) Stock Options - Nasdaq
www.nasdaq.com - July 10 at 4:00 PM
finance.yahoo.com logoImplied Volatility Surging for Array BioPharma Inc. (ARRY) Stock Options
finance.yahoo.com - July 10 at 4:00 PM
nasdaq.com logoArray BioPharma Submits NDAs For Binimetinib & Encorafenib In Advanced Melanoma
www.nasdaq.com - July 5 at 4:40 PM
finance.yahoo.com logoArray BioPharma Submits New Drug Applications To FDA For Binimetinib And Encorafenib In Advanced Melanoma
finance.yahoo.com - July 5 at 4:40 PM
americanbankingnews.com logo$30.60 Million in Sales Expected for Array BioPharma Inc. (ARRY) This Quarter
www.americanbankingnews.com - July 1 at 9:44 AM
americanbankingnews.com logoZacks: Analysts Anticipate Array BioPharma Inc. (ARRY) Will Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - June 29 at 7:49 AM
nasdaq.com logoCommit To Buy Array BioPharma At $4, Earn 13.8% Using Options - Nasdaq
www.nasdaq.com - June 27 at 3:47 PM
finance.yahoo.com logoETFs with exposure to Array BioPharma, Inc. : June 27, 2017
finance.yahoo.com - June 27 at 3:47 PM
americanbankingnews.com logoArray BioPharma Inc. (ARRY) Upgraded at BidaskClub
www.americanbankingnews.com - June 24 at 10:58 PM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Array BioPharma (ARRY) Stock?
finance.yahoo.com - June 23 at 4:15 PM
prnewswire.com logoPre-Market Technical Recap on Biotech Stocks -- Array BioPharma ... - PR Newswire (press release)
www.prnewswire.com - June 21 at 4:31 PM
finance.yahoo.com logoArray BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : ARRY-US : June 21, 2017
finance.yahoo.com - June 21 at 4:31 PM
nasdaq.com logoARRY Crosses Above Key Moving Average Level
www.nasdaq.com - June 21 at 2:21 AM
finance.yahoo.com logoETFs with exposure to Array BioPharma, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 4:20 PM
americanbankingnews.com logoArray BioPharma Inc. (ARRY) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - June 16 at 8:17 AM

Social

Chart

Array BioPharma (ARRY) Chart for Friday, August, 18, 2017

This page was last updated on 8/18/2017 by MarketBeat.com Staff